<track id="1517j"></track>

      <pre id="1517j"></pre>

          <ruby id="1517j"><ruby id="1517j"><b id="1517j"></b></ruby></ruby>
          <address id="1517j"></address>
          <track id="1517j"><strike id="1517j"><ol id="1517j"></ol></strike></track>

          <pre id="1517j"></pre>

          
          
          <track id="1517j"></track>
          <track id="1517j"></track>

          <track id="1517j"></track>

            <pre id="1517j"></pre><track id="1517j"></track>
                  • EI
                  • Scopus
                  • 食品科學與工程領域高質量科技期刊分級目錄第一方陣T1
                  • DOAJ
                  • EBSCO
                  • 北大核心期刊
                  • 中國核心學術期刊RCCSE
                  • JST China
                  • FSTA
                  • 中國精品科技期刊
                  • 中國農業核心期刊
                  • CA
                  • WJCI
                  • 中國科技核心期刊CSTPCD
                  • 中國生物醫學SinoMed
                  中國精品科技期刊2020
                  張亞碩,阿如娜,馬鑫彥,等. 荔枝核提取物干預非酒精性脂肪肝病的網絡藥理學分析及驗證[J]. 食品工業科技,2023,44(18):10?19. doi: 10.13386/j.issn1002-0306.2022100271.
                  引用本文: 張亞碩,阿如娜,馬鑫彥,等. 荔枝核提取物干預非酒精性脂肪肝病的網絡藥理學分析及驗證[J]. 食品工業科技,2023,44(18):10?19. doi: 10.13386/j.issn1002-0306.2022100271.
                  ZHANG Yashuo, A Runa, MA Xinyan, et al. Network Pharmacological Analyze and Experimental Verification of Lychee Kernel Extract Intervene of Non-alcoholic Fatty Liver Disease[J]. Science and Technology of Food Industry, 2023, 44(18): 10?19. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022100271.
                  Citation: ZHANG Yashuo, A Runa, MA Xinyan, et al. Network Pharmacological Analyze and Experimental Verification of Lychee Kernel Extract Intervene of Non-alcoholic Fatty Liver Disease[J]. Science and Technology of Food Industry, 2023, 44(18): 10?19. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022100271.

                  荔枝核提取物干預非酒精性脂肪肝病的網絡藥理學分析及驗證

                  Network Pharmacological Analyze and Experimental Verification of Lychee Kernel Extract Intervene of Non-alcoholic Fatty Liver Disease

                  • 摘要: 目的:運用網絡藥理學的方法,研究荔枝核提取物(Lychee kernel extract,LKE)干預非酒精性脂肪性肝?。∟onalcoholic fatty liver disease,NAFLD)的作用及分析潛在機制。方法:通過中藥系統藥理學數據庫和分析平臺(TCMSP)獲取荔枝核的成分和作用靶點,通過疾病靶點數據Genecard獲取NAFLD的疾病靶點,然后取交集,通過Cytoscape獲取通路-靶點互作網絡圖,利用微生信網站進行 GO生物過程分析和 KEGG 通路富集分析。建立飲食誘導的肥胖(diet-induced obsisity,DIO)小鼠NAFLD動物模型并用LKE灌胃給藥。HE染色觀察肝臟脂質變化;試劑盒檢測TG、TC、ALT、AST含量。結果:獲得荔枝核潛在活性成分18個,與NAFLD疾病交集靶點52個,關鍵靶點為INS、TNF、HSP90AA1,通過KEGG通路富集篩選得到信號通路20條,主要為癌癥通路(pathways in cancer)、動脈粥樣硬化通路(Fluid shear stress and atherosclerosis)、糖尿病并發癥的信號通路(AGE-RAGE signaling pathway in diabetic complications);模型組小鼠肝臟病變嚴重,給藥組小鼠肝臟病變相對于模型組明顯減輕,給藥組小鼠血清轉氨酶也明顯降低,接近正常組,給藥組血脂代謝也趨于正常組,且差異均具有顯著性(P<0.05)。結論:荔枝核可能通過作用于INS、TNF、HSP90AA1等靶點,調節脂質和動脈粥樣硬化通路等起到治療NAFLD的作用。

                     

                    Abstract: Objective: To investigate the effect and potential mechanism of lychee kernel extract in the intervention of non-alcoholic fatty liver disease (Nonalcoholic fatty liver disease, NAFLD) based on network pharmacology. Methods: The components and action targets of litchi nuclei were obtained from the Pharmacology Database and Analysis Platform (TCMSP) within the Chinese Medicine System, the disease targets of NAFLD were obtained using disease target data from GeneCard, the intersection and pathway-target interaction network diagram were obtained through Cytoscape, and the GO bioprocess analysis and KEGG pathway enrichment analysis were performed using Bioinformatics website. This study established an animal model with diet-induced obsisity mouse NAFLD and administered LKE via the gastric route. HE staining indicated lipid changes in the liver. The biological kits detect content of TG, TC, ALT, and AST. Results: Eighteen potential active ingredients of litchi nuclei were identified, and 52 targets intersected with NAFLD disease. The key targets were INS, TNF, and HSP90AA1. KEGG channel enrichment filtered 20 signal pathways, the main ones include: Pathways in cancer, fluid shear stress and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications. The liver lesions of the mice in the model group were severe, the liver lesions of the mice in the drug group were significantly reduced compared with the model group, and the serum transaminases of the mice in the drug group were also significantly reduced, which was close to the normal group, and the blood lipid metabolism of the drug group also tended to be normal group,and the differences were significant (P<0.05). Conclusion: Litchi nuclei might play a role in the treatment of NAFLD by acting on such targets as INS, TNF and HSP90AA1, and modulate lipid and atherosclerotic pathways.

                     

                  /

                  返回文章
                  返回
                  亚洲一区精品黄